RecruitingNCT03657745

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

An Observational Trial of Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy


Sponsor

Alzheimer's Light LLC

Enrollment

2,000 participants

Start Date

Jan 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.


Eligibility

Min Age: 50 Years

Inclusion Criteria2

  • Alzheimer's disease
  • Cognitive Impairment

Exclusion Criteria2

  • any previously noted epileptic seizures, including febrile seizures.
  • any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.

Interventions

DEVICECombination of 40Hz light and cognitive therapy (ALZLIFE)

Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE


Locations(1)

Andrey Vyshedskiy

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03657745


Related Trials